Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

- Weber, Jeffrey S., Schadendorf, Dirk, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Del Vecchio, Michele, Brown, Michael P., Rutkowski, P, Haydon, A, Grob, J-J, Schachter, J, Queirolo, P, de la Cruz-Merino, L, van der Westhuizen, Andre, Menzies, AM, Re, S, Larkin, James, Bas, T, de Pril, V, Braverman, J, Tenney, DJ, Tang, H, Long, GV, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas

Association of pembrolizumab with tumor response and survival among patients with advanced melanoma

- Ribas, Antoni, Hamid, Omid, Gangadhar, Tara C., Hersey, Peter, Dronca, Roxana, Joseph, Richard W., Zarour, Hassane, Chmielowski, Bartosz, Lawrence, Donald P., Algazi, Alain, Rizvi, Naiyer A., Hoffner, Brianna, Daud, Adil, Mateus, Christine, Gergich, Kevin, Lindia, Jill A., Giannotti, Maxine, Li, Xiaoyun Nicole, Ebbinghaus, Scott, Kang, S. Peter, Robert, Caroline, Hodi, F. Stephen, Wolchok, Jedd D., Kefford, Richard, Joshua, Anthony M., Patnaik, Amita, Hwu, Wen-Jen, Weber, Jeffrey S.

Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab

- Hodi, F. Stephen, Hwu, Wen-Jen, Joshua, Anthony M., Hersey, Peter, Dronca, Roxana, Joseph, Richard, Hille, Darcy, Xue, Dahai, Li, Xiaoyun Nicole, Kang, S. Peter, Ebbinghaus, Scot, Perrone, Andrea, Kefford, Richard, Wolchok, Jedd D., Weber, Jeffrey S., Daud, Adil, Hamid, Omid, Patnaik, Amita, Ribas, Antoni, Robert, Caroline, Gangadhar, Tara C.

Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

- Daud, Adil I, Wolchok, Jedd D., Joseph, Richard, Gangadhar, Tara C., Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K., Li, Xiaoyun Nicole, Emancipator, Kenneth, Robert, Caroline, Dolled-Filhart, Marisa, Kang, S. Peter, Ebbinghaus, Scot, Hamid, Omid, Hwu, Wen-Jen, Weber, Jeffrey S., Ribas, Antoni, Hodi, F. Stephen, Joshua, Anthony M., Kefford, Richard, Hersey, Peter

Pharmacodynamic effects and mechanisms of resistance to Vemurafenib in patients with metastatic melanoma

- Trunzer, Kerstin, Pavlick, Anna C., Hersey, Peter, Long, Georgina V., Lawrence, Donald, Ott, Patrick A., Amaravadi, Ravi K., Lewis, Karl D., Puzanov, Igor, Lo, Roger S., Koehler, Astrid, Kockx, Mark, Schuchter, Lynn, Spleiss, Olivia, Schell-Steven, Annette, Gilbert, Houston N., Cockey, Louise, Bollag, Gideon, Lee, Richard J., Joe, Andrew K., Sosman, Jeffrey A., Ribas, Antoni, Gonzalez, Rene, McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T., Kim, Kevin B., Weber, Jeffrey S.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma

- Hamid, Omid, Robert, Caroline, Dronca, Roxana, Gangadhar, Tara C., Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M., Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Daud, Adil, Tumeh, Paul C., Chmielowski, Bartosz, Ebbinghaus, Scot W., Li, Xiaoyun Nicole, Kang, S. Peter, Ribas, Antoni, Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D., Hersey, Peter, Joseph, Richard W., Weber, Jeffrey S.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

- Sosman, Jeffery A., Kim, Kevin B., Hersey, Peter, Kefford, Richard, Lawrence, Donald, Puzanov, Igor, Lewis, Karl D., Amaravadi, Ravi K., Chmielowski, Bartosz, Lawrence, H. Jeffrey, Shyr, Yu, Ye, Fei, Schuchter, Lynn, Gonzalez, Rene, Pavlick, Anna C., Weber, Jeffrey S., McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T.